Skip to content
design lab self-driving nissan toyota ford duke stanford e-hmi

Design Lab Collaborates with Amgen to Explore Adoption of Medical Therapies

Design Lab Collaborates with Amgen to Explore Adoption of Medical Therapies

Design Lab Collaborates with Amgen to Explore Adoption of Medical Therapies

The Design Lab has recently embarked on an exciting collaboration with Amgen to explore the mechanisms driving patients to adopt certain medication therapies.  Dr. Eliah Arnoff-Spencer, senior research scientist Colleen Emmenegger, and researcher Lars Mueller of the Design Lab, received a grant to work on a project aimed at understanding the factors that play a role in key medical decisions through applying human-centered design to healthcare.

Through specifically focusing on the elements of automation and trust within different medical capacities, the team seeks to uncover why patients choose to adopt and either continue or subsequently stop certain therapies.   Automated sensors for diabetes and certain medical treatments are among the areas that the team will target within the healthcare space. Emmenegger, the director of the automation program at The Design Lab, noted that trust is a common theme that transcends both the fields of autonomous vehicles and medicine and will serve as a focal point throughout the project.  

The first step in fostering a shared understanding around patient decisions is to delve deeply into the literature surrounding the adoption and continuation of medical therapies.  Following an analysis of the important insights extracted from existing research, the team plans to conduct interviews with a network of stakeholders within the medical space such as physicians, caregivers, supporters and members of product therapy marketing groups.  Developing an understanding of how trust impacts the community and patients will inform the next phases of the project which will consist of observational studies and site visits of patient homes, doctor’s offices and pharmacies. “It’s never just a single person interacting with a single product – multiple people are always involved and there’s a very distributed nature to these interactions,” says Emmenegger. 

The project marks the start of a long-term partnership with Amgen.  Through interacting with individuals who are involved in making key medical decisions and are knowledgeable about the medical therapy adoption life cycle, Emmenegger is looking forward to learning about the impacts of the study within the larger community.  “This project will teach us not only about trust but also about how to humanize healthcare.”

The Design Lab has recently embarked on an exciting collaboration with Amgen to explore the mechanisms driving patients to adopt certain medication therapies.  Dr. Eliah Arnoff-Spencer, senior research scientist Colleen Emmenegger, and researcher Lars Mueller of the Design Lab, received a grant to work on a project aimed at understanding the factors that play a role in key medical decisions through applying human-centered design to healthcare.

Through specifically focusing on the elements of automation and trust within different medical capacities, the team seeks to uncover why patients choose to adopt and either continue or subsequently stop certain therapies.   Automated sensors for diabetes and certain medical treatments are among the areas that the team will target within the healthcare space. Emmenegger, the director of the automation program at The Design Lab, noted that trust is a common theme that transcends both the fields of autonomous vehicles and medicine and will serve as a focal point throughout the project.  

The first step in fostering a shared understanding around patient decisions is to delve deeply into the literature surrounding the adoption and continuation of medical therapies.  Following an analysis of the important insights extracted from existing research, the team plans to conduct interviews with a network of stakeholders within the medical space such as physicians, caregivers, supporters and members of product therapy marketing groups.  Developing an understanding of how trust impacts the community and patients will inform the next phases of the project which will consist of observational studies and site visits of patient homes, doctor’s offices and pharmacies. “It’s never just a single person interacting with a single product – multiple people are always involved and there’s a very distributed nature to these interactions,” says Emmenegger. 

The project marks the start of a long-term partnership with Amgen.  Through interacting with individuals who are involved in making key medical decisions and are knowledgeable about the medical therapy adoption life cycle, Emmenegger is looking forward to learning about the impacts of the study within the larger community.  “This project will teach us not only about trust but also about how to humanize healthcare.”

The Design Lab has recently embarked on an exciting collaboration with Amgen to explore the mechanisms driving patients to adopt certain medication therapies.  Dr. Eliah Arnoff-Spencer, senior research scientist Colleen Emmenegger, and researcher Lars Mueller of the Design Lab, received a grant to work on a project aimed at understanding the factors that play a role in key medical decisions through applying human-centered design to healthcare.

Through specifically focusing on the elements of automation and trust within different medical capacities, the team seeks to uncover why patients choose to adopt and either continue or subsequently stop certain therapies.   Automated sensors for diabetes and certain medical treatments are among the areas that the team will target within the healthcare space. Emmenegger, the director of the automation program at The Design Lab, noted that trust is a common theme that transcends both the fields of autonomous vehicles and medicine and will serve as a focal point throughout the project.  

The first step in fostering a shared understanding around patient decisions is to delve deeply into the literature surrounding the adoption and continuation of medical therapies.  Following an analysis of the important insights extracted from existing research, the team plans to conduct interviews with a network of stakeholders within the medical space such as physicians, caregivers, supporters and members of product therapy marketing groups.  Developing an understanding of how trust impacts the community and patients will inform the next phases of the project which will consist of observational studies and site visits of patient homes, doctor’s offices and pharmacies. “It’s never just a single person interacting with a single product – multiple people are always involved and there’s a very distributed nature to these interactions,” says Emmenegger. 

The project marks the start of a long-term partnership with Amgen.  Through interacting with individuals who are involved in making key medical decisions and are knowledgeable about the medical therapy adoption life cycle, Emmenegger is looking forward to learning about the impacts of the study within the larger community.  “This project will teach us not only about trust but also about how to humanize healthcare.”

Read Next

SPUR Team 9

This project aims to bridge the communication gap between faculty and undergraduate students at UC…

Opinion: Becoming a World Design Capital would improve life in San Diego-Tijuana

San Diego Union Tribune Op-Ed by Mayor Todd Gloria

I believe that San Diego is one of the world’s greatest cities, and together with our sister city Tijuana, we form a dynamic, multicultural area unlike anywhere else. Both as a lifelong San Diegan and the mayor of San Diego, I am proud that our city is one of two finalists in the running to be selected as the World Design Capital in 2024. Earning this designation would highlight the unique character of our binational region and show the entire world that our diversity is our strength.

Just as design has continued to address complex challenges at our border and between our cities, we continue to improve the quality of life in San Diego through thoughtful, human-centered design. The transformation of the Plaza de Panama at Balboa Park, Waterfront Park and Liberty Station are only a few examples of how we’ve begun to think about public space differently in San Diego over the last decade.
Design Lab Ibm

IBM Design Thinking Workshop at The Design Lab

IBM believes in design thinking. And design doing. So much so that throughout the company,…

Design Lab Communitycrit Narges Mahyar Steven Dow

CommunityCrit Gives Community Members a Newfound Voice

Actively engaging the public in urban design planning is essential to both establishing a strong…

SPUR Team 9

This project aims to bridge the communication gap between faculty and undergraduate students at UC…

San Diego/Tijuana is finalist to become a World Design Capital

San Diego Union Tribune

The San Diego/Tijuana region is a finalist to become a World Design Capital that could mean a year-long promotion of the binational region.

Winners are chosen based on how each region effectively incorporates design across their economic, technological, social, cultural, political and environmental sectors . More than just having a fancy title, winning means a year of events to promote the region, including a street festival, a one-day celebration highlighting the winner’s designs and a design conference that should bring people from around the globe.

“This is an incredibly exciting opportunity to not only showcase our bi-national region as a longstanding design and innovation powerhouse,” she wrote, “but to also shape the narrative around what it means to be a 21st century metropolis, [says Michèle Morris, President of the Design Forward Alliance and Associate Director of UCSD Design Lab]."
Back To Top